Join the club for FREE to access the whole archive and other member benefits.

Verve Therapeutics

Biotechnology company

Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.

Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people worldwide at risk of coronary artery disease.

Visit website:



People at Verve Therapeutics

Zachary Glass

Formulation scientist at Verve therapeutics

Verve Therapeutics News

Single-dose gene-editing therapy offers permanent solution to high cholesterol levels

New Scientist - 14-Nov-2023

Early results show promise in eliminating the need for lifelong statins


Verve Therapeutics' gene editing therapy may cure heart attacks once and for all

Bloomberg - 06-May-2022

Trials underway to test the safety, but affordability and acceptance of gene therapy are major concerns


Gene editing lowered blood level cholesterol and triglycerides in monkeys

New York Times - 27-Jun-2020

Could prevent not only the complications but the heart disease per se in the future